QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
Free Trial
NASDAQ:JNCE

Jounce Therapeutics (JNCE) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free JNCE Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$1.88
▼
$1.93
50-Day Range
$1.84
▼
$1.94
52-Week Range
$0.58
▼
$5.87
Volume
11.60 million shs
Average Volume
2.46 million shs
Market Capitalization
$98.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
JNCE stock logo

About Jounce Therapeutics Stock (NASDAQ:JNCE)

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

JNCE Stock News Headlines

November 27, 2023 | bizjournals.com
San Diego VC, OrbiMed make competing buyout offers for struggling Theseus
September 19, 2023 | tmcnet.com
Jounce Media Designates Yahoo Backstage as the Open Web's Largest MFA-Free Supply Source
April 16, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
September 18, 2023 | finance.yahoo.com
Kargo Is Industry’s Only Scaled 100% Premium SSP According To Jounce Media
September 5, 2023 | tmcnet.com
Mediavine Represents the Largest Percentage of DEI-owned Websites, Per Data from Jounce Media
May 5, 2023 | benzinga.com
Board Member at Jounce Therapeutics Exercises Options Worth $324K
May 4, 2023 | benzinga.com
Board Member at Jounce Therapeutics Exercises Options Worth $172K
May 4, 2023 | benzinga.com
Jounce Therapeutics Director Acquires 51,400 Shares After Exercising Company Stock Options
April 16, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
May 4, 2023 | benzinga.com
Jounce Therapeutics Board Member Acquires 1,883,269 Shares After Exercising Company Stock Options
May 3, 2023 | finance.yahoo.com
Jounce Therapeutics Announces Closing of Tender Offer
April 29, 2023 | seekingalpha.com
JNCE Jounce Therapeutics, Inc.
April 17, 2023 | finance.yahoo.com
The past five years for Jounce Therapeutics (NASDAQ:JNCE) investors has not been profitable
March 29, 2023 | benzinga.com
What is Wall Street's Target Price for Jounce Therapeutics Inc (JNCE) Stock Monday?
March 27, 2023 | msn.com
Buyout Offer Sends Jounce Jumping 20%
March 27, 2023 | marketwatch.com
Jounce Therapeutics Shares Rally on Buyout Deal >JNCE
March 27, 2023 | marketwatch.com
Jounce Therapeutics Agrees to Buyout, Drops Redx Deal >JNCE
March 27, 2023 | finance.yahoo.com
Jounce dumps Redx Pharma for acquisition by Concentra; to cut 84% of jobs
March 23, 2023 | benzinga.com
Moore Kuehn Encourages JNCE, USX, INDT, and BHWB Investors to Contact Law Firm
March 17, 2023 | 247wallst.com
Tang Capital Partners Now Owns 10.2% of Jounce Therapeutics
March 16, 2023 | finance.yahoo.com
Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer
March 16, 2023 | finance.yahoo.com
Jounce (JNCE) Up 41% on Buyout Offer From Concentra Biosciences
March 15, 2023 | benzinga.com
10% Owner of Jounce Therapeutics Makes $85K Buy
March 15, 2023 | finance.yahoo.com
Why Jounce Therapeutics Stock Is Moving Higher Today?
March 15, 2023 | markets.businessinsider.com
Concentra Biosciences Proposes To Acquire Jounce Therapeutics - Quick Facts
March 15, 2023 | msn.com
Tang Capital Partners Now Owns 10.20% of Jounce Therapeutics (JNCE)
March 15, 2023 | marketwatch.com
Jounce Therapeutics Jumps Premarket on Buyout Bid >JNCE
See More Headlines
Receive JNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
4/16/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:JNCE
CUSIP
N/A
CIK
1640455
Web
www.jouncetx.com
Phone
(857) 259-3840
Fax
N/A
Employees
137
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($2.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-50,920,000.00
Net Margins
N/A
Pretax Margin
-61.93%
Return on Equity
-30.90%
Return on Assets
-26.31%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.37
Quick Ratio
8.37

Sales & Book Value

Annual Sales
$82 million
Price / Sales
1.21
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.54 per share
Price / Book
0.53

Miscellaneous

Outstanding Shares
52,630,000
Free Float
48,993,000
Market Cap
$98.94 million
Optionable
Optionable
Beta
0.75
Ten Starter Stocks For Beginners to Buy Now Cover
Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Kimberlee Cobleigh Drapkin
    President, Chief Financial Officer & Treasurer
  • Eric Laub
    Head-Investor & Media Relations
  • Ted Harding
    Senior Vice President-Human Resources
  • Jacquelyn Fahey Sandell
    Secretary & Chief Legal Officer
  • Allison Nance
    VP-Regulatory Affairs & Quality Assurance

Key Competitors

View All Competitors

JNCE Stock Analysis - Frequently Asked Questions

How were Jounce Therapeutics' earnings last quarter?

Jounce Therapeutics, Inc. (NASDAQ:JNCE) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.15. During the same period in the previous year, the business posted ($0.73) EPS.

What is Richard Murray Ph.D's approval rating as Jounce Therapeutics' CEO?

45 employees have rated Jounce Therapeutics Chief Executive Officer Richard Murray Ph.D on Glassdoor.com. Richard Murray Ph.D has an approval rating of 97% among the company's employees. This puts Richard Murray Ph.D in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jounce Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jounce Therapeutics investors own include Exelixis (EXEL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), CRISPR Therapeutics (CRSP), Novavax (NVAX), Mylan (MYL), Progenics Pharmaceuticals (PGNX), Adaptimmune Therapeutics (ADAP), Incyte (INCY) and Nektar Therapeutics (NKTR).

When did Jounce Therapeutics IPO?

Jounce Therapeutics (JNCE) raised $76 million in an IPO on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

This page (NASDAQ:JNCE) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Can't believe it's happening again
Manward Press
He Is Giving Away Bitcoin
Crypto Swap Profits
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
Biden’s $374B Giveaway Into This Sector
DTI
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Options trading has suddenly become more reliable.
Eagle Publishing
Top 5 AI Stocks to Buy for 2024
Market Moving Trends